Michael Derks, PhD

Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom

  • 1Article
  • 1.1KReads1
  • 2026Active
  • 8Collaborators

1 Read counts for articles published before 2020 may include some non-human traffic.

About

Michael Derks, PhD is affiliated with Roche Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom. Michael Derks has contributed 1 peer-reviewed article published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders in 2026. Their work focuses on Cognition and Schizophrenia/Schizoaffective Disorders.

Publications

JCP
Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia
Original Research

Phase 2b Study to Evaluate Basmisanil as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia

April 15, 2026

Although basmisanil did not improve cognitive deficits, the results offer insight into factors that should facilitate design of more informative trials.
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe